DigestRedComo funciona
Red
/
Empresas
Ni
No verificado

Nimbus Therapeutics, LLC

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
06/01/2026
Mercado laboral
Industria
Ciencia
Fitness
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
19/12/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
25/04/2025
Industria
Oncología
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
07/03/2025
Mercado laboral
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
25/02/2025
Oncología
Salud
Farmacéutica
Cardiología
Biotecnología
Mercado laboral
Industria
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
07/11/2024
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
23/10/2024
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0
09/10/2024
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Fuente
Nimbus Therapeutics, LLC
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0